NeOnc Technologies Holdings, Inc. (NTHI)

NASDAQ: NTHI · Real-Time Price · USD

5.00

+0.12 (2.46%)

Jul 11, 2025, 1:28 PM - Market open

NTHI Employees

NeOnc Technologies Holdings had 8 employees as of December 31, 2023.

Employees

8

Change

n/a

Growth

n/a

Revenue / Employee

$9,999

Profits / Employee

-$5,870,184

Market Cap

95.13M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	8	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

NTHI News

3 days ago - NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform - GlobeNewsWire
5 weeks ago - NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs - GlobeNewsWire
3 months ago - NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets - GlobeNewsWire
3 months ago - NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September - GlobeNewsWire
3 months ago - NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President - GlobeNewsWire
3 months ago - NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy - GlobeNewsWire
3 months ago - NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas - GlobeNewsWire
3 months ago - NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments - GlobeNewsWire